let's recode what's possible
Chief Financial Officer
Jason F. Cole, Esq.
Chief Operating & Legal Officer
Rich Colvin, MD, PhD
Chief Medical Officer
Head of Europe
Doug has more than 20 years of Pricing & Market Access experience, including roles with Eli Lilly & Company, Amgen, Millennium/Takeda Oncology and now bluebird bio. In that time, he has led or overseen the preparation of market access strategies for products in early development, pivotal study planning, launch, and post launch lifecycle management. While addressing market access challenges from a variety of vantage points including Global, European Regional, and U.S. roles he’s built teams, processes, and a knowledgebase that enables the execution of market access strategies which anticipate and meet the needs of access decision makers in an increasing challenging market access environment.
Chief Regulatory Officer
In her tenure at bluebird, Anne-Virginie played a key role in leading the teams that managed the approvals of ZYNTEGLO and SKYSONA in Europe, as well as the approval of ABECMA in the US in 2021 in partnership with BMS. She is currently highly engaged in the efforts to bring bluebird bio’s late stage gene therapy products to patients in the US, while supporting the development of early stage innovative gene edited products. Passionate about advanced therapy, Anne-Virginie has also actively participated, throughout the past 20 years, in shaping the US and European cell and gene therapy regulatory environment.
Prior to joining bluebird bio, Anne‑Virginie was an Executive Director at Voisin Consulting, leading projects involving the design and implementation of regulatory strategies for medicinal products, with a specific focus on rare diseases, cancer and advanced therapies. Her experience spans from early development through commercialization, including lead roles on the registration of several orphan drugs, and regulatory expertise on both sides of the Atlantic.
Anne‑Virginie holds a Master of Science in Environmental Health Sciences from the UCLA School of Public Health, as well as a B.S. in Chemical Engineering from the California Institute of Technology.
Philip D. Gregory, D. Phil.
Chief Scientific Officer
Chief Operating Officer, Oncology
Chief Commercial Officer
President, Severe Genetic Diseases
Board of Directors
Daniel S. Lynch
Chairman - Independent
John O. Agwunobi, M.D.
Agwunobi previously served as co-president and chief health and nutrition officer, directing the company’s nutrition philosophy. Since joining the company in 2016, Agwunobi has worked closely with Herbalife Nutrition independent distributors and customers, ensuring that the company continuously innovates in the areas of product development, technology, marketing and distributor sales. He also led the Herbalife Nutrition Institute, the Herbalife Nutrition Advisory Board, and the Herbalife Dietetic Advisory Board and worked with the company’s Ph.D.s and scientists to integrate nutrition science into Herbalife Nutrition products.
Agwunobi brings a wealth of experience from both the public and private sectors to his role. Most notably, in the private sector, he served as senior vice president and president of health and wellness for the world’s largest retailer, Walmart, where he led a team of over 65,000 and grew the business from $25 billion to over $30 billion. In the public sector, Agwunobi served as Florida’s secretary of health and later as an admiral in the U.S. Public Health Services Commissioned Corps and the assistant secretary of health for the U.S. Department of Health and Human Services. In these roles, he was responsible for disease prevention and health promotion. He oversaw the Centers for Disease Control, the National Institutes of Health, the Food and Drug Administration, the office of the U.S. Surgeon General, and numerous other public health offices and programs.
Agwunobi has a broad educational background that includes a master's degree in public health from Johns Hopkins University and a master's degree in business administration from Georgetown University. He completed his pediatric residency at Howard University and is currently a licensed physician in Florida and Maryland. He serves on numerous boards, including the U.S. African Development Foundation and bluebird bio.
Wendy L. Dixon, Ph.D.
Formerly of Bristol-Myers Squibb Company
Ramy Ibrahim, MD
Dr. Ibrahim currently serves as Chief Medical Officer at bit.bio. Previously, Dr. Ibrahim was CMO at the Parker Institute for Cancer Immunotherapy. As part of his role, he built clinical trial management and the translational capabilities within the Institute that enabled the conduct of multi-center clinical trials across the Parker centers. In addition, he played a critical role in establishing Newco built around IP and discoveries generated from the member researchers. The support provided by PICI included seed funds, business plans and clinical development plans.
At AstraZeneca, Dr. Ibrahim was the vice president and Therapeutic area head for Immuno-Oncology clinical development, leading the global clinical team developing multiple immunotherapies. He led the team that designed and executed registrational studies that led to the approval of some of those agents such as Durvalumab in locally advanced NSCLC which transformed standard of care of those patients.
As a member of the Bristol-Myers Squibb Immuno-oncology program, he served on the Yervoy (ipilimumab) clinical team supporting the program from early phase II through multiple global launches of the first FDA-approved immune checkpoint inhibitor. In addition, he played a key role in early development for nivolumab (PD-1), PD-L1 and CD137 antibody.
Throughout his career, Dr. Ibrahim has been involved with global cancer immunotherapy societies such as ASCO, AACR, Society of Immunotherapy for Cancer (SITC), Friends of Cancer research, the Cancer Research Institute and Cancer Support Community (CSC). He is a trained medical oncologist, who conducted bench and clinical immunotherapy research at the cancer vaccine branch of the National Cancer Institute in Bethesda, MD.
William R. Sellers, M.D.
Core Institute Member, Broad Institute of MIT and Harvard
William R. Sellers, M.D. has served as a member of our board since September 2019. Dr. Sellers currently leads a research group focused on translating genomic discoveries into new therapeutics as a Core Institute Member at the Broad Institute of MIT and Harvard, and as a Professor of Medicine at the Dana-Farber Cancer Institute and Harvard Medical School. Previously, Dr. Sellers directed cancer drug discovery and early cancer clinical development at the Novartis Institutes for Biomedical Research overseeing scientists, clinicians and clinical staff on sites in Cambridge, East Hanover, Basel and Shanghai from 2005-2016. During his tenure he conceptualized and directed a collaboration with the Broad Institute on the Cancer Cell Line Encyclopedia, the development of the Novartis Primary Derived Xenograft Encyclopedia and large-scale efforts to functionally characterize the cancer genome. Along with Dr. Carl June, he co-chaired the CART research collaboration with the University of Pennsylvania that brought CTL019 to a recent FDA approval.
Dr. Sellers was previously an Associate Professor of Medicine at the Dana-Farber Cancer Institute and Harvard Medical School and an Associate Member of the Broad Institute. Together with Matthew Meyerson, he initiated and developed large-scale efforts to re-sequence genes in diverse cancer types, which led to the development of the widely used GISTIC algorithm, the discovery of EGFR mutations in lung adenocarcinoma and the discovery of the oncogenic role of the MITF gene in melanoma. In addition, his work advanced the understanding of the molecular mechanisms of growth regulation of the PTEN tumor suppressor gene.
Dr. Sellers received his B.S. from Georgetown University in 1982 and M.D. from the University of Massachusetts Medical School in 1986. He completed residency training in Internal Medicine at the University of California San Francisco in 1989 and trained in Medical Oncology at the Dana-Farber Cancer Institute. Dr. Sellers is a former member of the National Cancer Advisory Board.
Formerly of Change Healthcare Holdings, Inc.
Formerly of Johnson & Johnson
Denice Torres has served as a member of our board of directors since August 2020. She has 25 years of management experience in pharmaceuticals, medical devices, and consumer healthcare.
From 2005-2017, Denice served in senior leadership roles at Johnson & Johnson, including Chief Strategy and Transformation Officer for the global medical device business. Denice is credited for leading one of the most significant transformations in J&J history. Following a series of recalls and the initiation of a consent decree, Denice assumed the role of President, McNeil Consumer Healthcare. From 2011-2015, she led the recovery of OTC brands, including the iconic Tylenol portfolio, by transforming the business operations, manufacturing and quality systems, commercialization approach, and creating high levels of employee engagement across all functions of the business. As a result, Healthcare Businesswoman Association (HBA) named Denice Woman of the Year in 2015. At J&J, Denice also served as President of Janssen Pharmaceuticals (CNS) where she drove turnaround growth by evolving operations, commercialization, patient focus, and building a high performing culture.
Before joining J&J, Denice had a highly successful, 14-year career at Lilly where she was the executive director of global neuroscience and director of U.S. women’s health. She is founder of The Mentoring Place, a volunteer platform that focuses on helping accelerate the careers of women.
Denice received a Bachelor of Science in Psychology from Ball State University, Doctor of Jurisprudence from Indiana University, and Master’s in Business Administration from the University of Michigan. She is a member of the Michigan Bar Association.
You are now leaving www.bluebirdbio.com
Links to sites outside of this website are provided as a resource to the viewer. bluebird bio accepts no responsibility for the content of linked sites.